Park Samuel U, Ferrer Jasmine V, Javitch Jonathan A, Kuhn Donald M
Department of Psychiatry, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, and The John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan 48201, USA.
J Neurosci. 2002 Jun 1;22(11):4399-405. doi: 10.1523/JNEUROSCI.22-11-04399.2002.
Peroxynitrite (ONOO(-)) has been implicated as a causative factor in dopamine neuronal damage resulting from exposure to methamphetamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and it may be involved in the etiology of Parkinson's Disease. ONOO(-) causes a concentration-dependent and irreversible reduction in dopamine uptake by EM4 cells stably expressing the human dopamine transporter (hDAT). The effect of ONOO(-) is manifested as a reduction in V(max). Cysteine, dithiothreitol, glutathione, and N-acetyl-cysteine, reagents that interact directly with ONOO(-), prevent this inhibition, whereas a scavenger of hydroxyl radical (dimethylsulfoxide), hydrogen peroxide (catalase), and superoxide (superoxide dismutase) did not. Dopamine in the extracellular medium protects the hDAT from ONOO(-), whereas intracellular dopamine does not. Parachloromercuribenzoic acid and 2-aminoethyl methanethiosulfonate (MTSEA), which share with ONOO(-) the ability to modify cysteine sulfhydryls, also inhibit hDAT function. ONOO(-) treatment lowers cysteine-specific labeling of the hDAT by MTSEA-biotin, suggesting that ONOO(-) reacts with one or more cysteines in hDAT. A mutant of hDAT (X7C) in which all intracellular and extracellular loop cysteines were mutated was resistant to inhibition by ONOO(-). Sensitivity to ONOO(-) was restored in mutants of hDAT in which reduced cysteines were present only in the first (C135) and third (C342) intracellular loops (CD-DAT), or in which C342 alone had been reintroduced into X7C (X7C-M342C). These results indicate that the hDAT is inhibited by ONOO(-) through oxidation of cysteine 342. Our studies also substantiate the possibility that drugs known to decrease DAT function in vivo (e.g., methamphetamine and MPTP) may exert their effects through ONOO(-)-mediated oxidative stress.
过氧亚硝酸盐(ONOO(-))被认为是暴露于甲基苯丙胺和1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)导致多巴胺能神经元损伤的一个致病因素,并且它可能参与帕金森病的病因。ONOO(-)导致稳定表达人多巴胺转运体(hDAT)的EM4细胞对多巴胺的摄取呈浓度依赖性且不可逆地降低。ONOO(-)的作用表现为V(max)降低。半胱氨酸、二硫苏糖醇、谷胱甘肽和N-乙酰半胱氨酸,这些直接与ONOO(-)相互作用的试剂可防止这种抑制作用,而羟基自由基清除剂(二甲基亚砜)、过氧化氢(过氧化氢酶)和超氧阴离子(超氧化物歧化酶)则不能。细胞外培养基中的多巴胺可保护hDAT免受ONOO(-)的影响,而细胞内多巴胺则不能。对氯汞苯甲酸和2-氨基乙基甲硫代磺酸盐(MTSEA),它们与ONOO(-)一样具有修饰半胱氨酸巯基的能力,也抑制hDAT功能。用MTSEA-生物素处理ONOO(-)可降低hDAT的半胱氨酸特异性标记,表明ONOO(-)与hDAT中的一个或多个半胱氨酸发生反应。hDAT的一个突变体(X7C),其中所有细胞内和细胞外环半胱氨酸都发生了突变,对ONOO(-)的抑制具有抗性。在hDAT的突变体中恢复了对ONOO(-)的敏感性,这些突变体中仅在第一个(C135)和第三个(C342)细胞内环(CD-DAT)中存在还原型半胱氨酸,或者其中仅将C342重新引入X7C(X7C-M342C)。这些结果表明,hDAT通过半胱氨酸342的氧化被ONOO(-)抑制。我们的研究还证实了体内已知可降低DAT功能的药物(如甲基苯丙胺和MPTP)可能通过ONOO(-)介导的氧化应激发挥作用的可能性。